Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Sep 19, 2014
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress

Aug 11, 2014
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval

Aug 11, 2014
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results

Aug 4, 2014
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call

Stock Quote (NASDAQ: MACK)


+ 0.05

Day High:

Day Low:


4:00 PM ET on Sep 19, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools